Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery

• DOI: 10.7326/m17-2341
• Publication Date: 2018-02-19T23:41:26Z
• Authors: Michelle M. Graham; Daniel I. Sessler; Joel L. Parlow; Bruce M. Biccard; Gordon Guyatt; Kate Leslie; Matthew T.V. Chan; Christian S. Meyhoff; Denis Xavier; Alben Sigamani; Priya A. Kumar; Marko Mrkobrada; Deborah J. Cook; Vikas Tandon; Jesus Alvarez-Garcia; Juan Carlos Villar; Thomas W. Painter; Giovanni Landoni; Edith Fleischmann; Andre Lamy; Richard Whitlock; Yannick Le Manach; Meylin Aphang-Lam; Juan P. Cata; Peggy Gao; Nicolaas C.S. Ter...; Pamidimukkala V. ...; Kim A. Jamieson; Amal Bessissow; Gabriela R. Mendoza; Silvia Ramirez; Pierre A. Diemunsch; Salim Yusuf; P.J. Devereaux
• Keywords: Male; Platelet Aggregation Inhibitors/adverse effects; Hazard ratio; Myocardial Infarction; 610; Hemorrhage; Aspirin/adverse effects; Postoperative Complications/chemically induced; Clonidine; Drug Administration Schedule; Percutaneous coronary intervention; 03 medical and health sciences; Percutaneous Coronary Intervention; Postoperative Complications; 0302 clinical medicine; Drug Therapy; Hemorrhage/chemically induced; 616; Absolute risk reduction; Humans; Clonidine/therapeutic use; Hospital medicine; Stent implantation; Antihypertensive Agents; Aged; Antihypertensive Agents/therapeutic use; Surgical Procedures; Aspirin; https://purl.org/pe-repo/ocde/ford#3.02.27; Drugs; Middle Aged; Operative; 3. Good health; Myocardial infarction; Treatment Outcome; Surgical Procedures, Operative; Myocardial Infarction/prevention & control; Combination; Surgery; Drug Therapy, Combination; Female; Biomarkers/blood; Biomarkers; Platelet Aggregation Inhibitors

Uncertainty remains about the effects of aspirin in patients with prior percutaneous coronary intervention (PCI) having noncardiac surgery.To evaluate benefits and harms of perioperative aspirin in patients with prior PCI.Nonprespecified subgroup analysis of a multicenter factorial trial. Computerized Internet randomization was done between 2010 and 2013. Patients, clinicians, data collectors, and outcome adjudicators were blinded to treatment assignment. (ClinicalTrials.gov: NCT01082874).135 centers in 23 countries.Adults aged 45 years or older who had or were at risk for atherosclerotic disease and were having noncardiac surgery. Exclusions were placement of a bare-metal stent within 6 weeks, placement of a drug-eluting stent within 1 year, or receipt of nonstudy aspirin within 72 hours before surgery.Aspirin therapy (overall trial, n = 4998; subgroup, n = 234) or placebo (overall trial, n = 5012; subgroup, n = 236) initiated within 4 hours before surgery and continued throughout the perioperative period. Of the 470 subgroup patients, 99.9% completed follow-up.The 30-day primary outcome was death or nonfatal myocardial infarction; bleeding was a secondary outcome.In patients with prior PCI, aspirin reduced the risk for the primary outcome (absolute risk reduction, 5.5% [95% CI, 0.4% to 10.5%]; hazard ratio [HR], 0.50 [CI, 0.26 to 0.95]; P for interaction = 0.036) and for myocardial infarction (absolute risk reduction, 5.9% [CI, 1.0% to 10.8%]; HR, 0.44 [CI, 0.22 to 0.87]; P for interaction = 0.021). The effect on the composite of major and life-threatening bleeding in patients with prior PCI was uncertain (absolute risk increase, 1.3% [CI, -2.6% to 5.2%]). In the overall population, aspirin increased the risk for major bleeding (absolute risk increase, 0.8% [CI, 0.1% to 1.6%]; HR, 1.22 [CI, 1.01 to 1.48]; P for interaction = 0.50).Nonprespecified subgroup analysis with small sample.Perioperative aspirin may be more likely to benefit rather than harm patients with prior PCI.Canadian Institutes of Health Research.